230239 “Treatment Dust”: The Future of Nanotechnology in Large-Scale Disasters

Tuesday, November 9, 2010 : 2:30 PM - 2:50 PM

Jayfus Doswell, PhD , Juxtopia, LLC, Baltimore, MD
1.Background: Large-scale-disasters typically result in scarcity of medical resources and correspondingly require effective casualty care/triage management and increased performance of individual care providers with variable experience and at lower costs to significantly minimize preventable morbidity and mortality. Nanotechnology aims to advance the formulation of materials and manufacture of devices by controlling matter at the scale of 1–100 nanometers. Nanoinformatics describes the application of computer technology, information science and molecular simulations to organize, interpret, and predict the structure and physico-chemical properties of nanoparticles and nanomaterials. Nanotechnology has the potential of adding significant value to disaster response teams by providing a range of tools for disaster response teams ranging from lightweight and miniaturized diagnostic and biological detection devices to mini-robotics that assist disaster response team triage in response to massive casualty.

2.Objective/Purpose: The objective of this presentation is to educate participants about the value that nanotechnology provides for assisting disaster response teams administer effective trauma care to disadvantaged populations impacted by large-scale catastrophic events.

Learning Areas:
Clinical medicine applied in public health
Communication and informatics
Public health or related research

Learning Objectives:
1.)Discuss the future of nanotechnology for assisting disaster response teams provide large scale casualty care treatment. 2.)Discuss how nanotechnology may be used to improve the triage management process.

Presenting author's disclosure statement:

Qualified on the content I am responsible for because: I am qualified to present because I am a biotechnology research professor with previous experience conducting nanoinformatics research at the National Cancer Institute Center for Biomedical Informatics.
Any relevant financial relationships? No

I agree to comply with the American Public Health Association Conflict of Interest and Commercial Support Guidelines, and to disclose to the participants any off-label or experimental uses of a commercial product or service discussed in my presentation.